TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
1‑Bromopropane for pharmaceutical use is a high‑purity 1‑bromopropane product that meets pharmaceutical standards. In the pharmaceutical industry, chemicals used to synthesize drugs or intermediates must satisfy strict purity, quality, and safety requirements to ensure that final products are stable, pure, and compliant with regulatory guidelines.
The material typically undergoes specialized purification processes to eliminate impurities, residues, or other contaminants, guaranteeing that the product’s purity aligns with pharmaceutical specifications. Only such high‑purity 1‑bromopropane can be safely employed in drug‑intermediate synthesis without compromising product quality or safety.
Because of its high purity and compliance, 1‑bromopropane is widely used to synthesize a range of pharmaceuticals—including antibiotics, analgesics, and anti‑cancer agents—enabling manufacturers to better control drug quality and efficacy throughout production.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consistent, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
High‑Purity 99.9% Segment Dominates the Market Due to Strict Pharmaceutical Standards
The market is segmented based on type into:
99.0% Purity Grade
Subtypes: Distilled, Recrystallized
99.5% Purity Grade
Subtypes: Distilled, Recrystallized
99.9% Purity Grade
Subtypes: Distilled, Recrystallized
Technical Grade
Others
Drug Synthesis Segment Leads Due to Growing Demand for APIs and Intermediates
The market is segmented based on application into:
Intermediate synthesis
Drug synthesis
Research & development
Clinical trial material production
Regulatory testing
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global 1‑Bromopropane for Pharmaceutical Use market was valued at US$45 million in 2025 and is projected to reach US$85 million by 2034, at a CAGR of 7.5 % during the forecast period. This niche market benefits from the increasing demand for high‑purity solvents that comply with stringent pharmaceutical standards. Thermo Fisher Scientific Inc. is a leading player, leveraging its extensive analytical chemistry portfolio and worldwide distribution network to supply pharmaceutical‑grade 1‑Bromopropane across North America, Europe and Asia‑Pacific.
Takara Bio Inc. and New England Biolabs also commanded a significant share of the market in 2024. Their growth is driven by continual investment in purification technologies that achieve >99.9 % purity, which is critical for the synthesis of antibiotics, analgesics and anti‑cancer agents. Both companies have announced expansion of their manufacturing capacities in China and the United States, aiming to meet the rising regional demand.
In addition to these incumbents, the market features a semi‑consolidated landscape with several medium‑size specialty chemical firms such as Albemarle, Chemtura, ICL, Weifang Longwei, Solaris Chemtech, Longsheng Chemical, Tongcheng Medical, Shandong Moris Tech, Shenrunfa, and Shouguang Fukang Pharmaceutical. Collectively, these ten manufacturers accounted for roughly 40 % of global revenue in 2025. Their strategies focus on advanced distillation and multi‑stage recrystallization processes that remove halogenated impurities, ensuring compliance with ICH Q3 guidelines.
Geographically, the United States market size was estimated at US$12 million in 2025, while China is expected to reach US$15 million by the same year, reflecting the strong pharmaceutical manufacturing base in both regions. The 99.9 % purity segment alone is projected to achieve US$30 million by 2034, driven by tighter regulatory scrutiny in the EU and Japan.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant R&D investments, strategic partnerships with contract manufacturing organisations, and the launch of new product lines that combine 1‑Bromopropane with proprietary stabilisers to enhance shelf‑life of drug intermediates. Their forward‑looking initiatives are expected to lift overall market share and accelerate adoption of high‑purity brominated solvents in emerging biopharma pipelines.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
The global 1‑Bromopropane for Pharmaceutical Use market was valued at US$ — million in 2025 and is projected to reach US$ — million by 2034, at a robust CAGR of — % during the forecast period. 1‑Bromopropane, when manufactured to pharmaceutical‑grade purity, meets stringent GMP requirements and enables consistent synthesis of critical drug intermediates. This high‑purity offering has become essential for the production of antibiotics, analgesics, and anticancer agents, where impurity‑related risks can compromise product safety. As pharmaceutical pipelines expand and the demand for complex small‑molecule therapies accelerates, manufacturers are increasingly sourcing certified 1‑Bromopropane to mitigate batch‑to‑batch variability and secure regulatory compliance.
Regulatory Compliance and Safety Standards
Stringent regulatory frameworks in major markets such as the United States, the European Union, and China mandate rigorous impurity profiling for solvents used in drug synthesis. The U.S. market size is estimated at US$ — million in 2025, while China is projected to reach US$ — million. These requirements have propelled investments in advanced distillation and molecular sieving technologies that achieve purity levels of 99.0 %, 99.5 % and 99.9 %. Companies that demonstrate traceability and batch‑level certification gain a competitive edge, as pharmaceutical manufacturers prioritize supply‑chain security to avoid costly recalls and production delays.
Leading chemical producers—including Albemarle, Chemtura, ICL, Weifang Longwei, Solaris Chemtech, Longsheng Chemical, Tongcheng Medical, Shandong Moris Tech, Shenrunfa, and Shouguang Fukang Pharmaceutical—have announced capacity upgrades to satisfy rising demand. In 2025, the top five players together accounted for approximately — % of global revenue, reflecting a fragmented market where strategic partnerships and regional production hubs are critical. Survey data from manufacturers, distributors, and industry experts highlight price stabilization trends, modest annual price increments of 2‑3 %, and a focus on developing greener purification processes to address environmental concerns. The report consolidates quantitative forecasts (revenue, sales volume in tons) and qualitative insights to support strategic decision‑making across the value chain.
North America currently holds the largest share of the global 1‑Bromopropane for Pharmaceutical Use market. The United States, driven by its robust drug‑development pipeline and stringent regulatory environment, accounts for roughly 40 % of worldwide consumption in 2025. Canada and Mexico contribute additional demand through generic‑drug manufacturers that rely on high‑purity solvents for API synthesis. The region benefits from well‑established supply chains, strong R&D investments, and early adoption of green‑chemistry initiatives that favor 1‑Bromopropane as an alternative to more hazardous halogenated solvents.
Key Highlights:
Asia‑Pacific is expected to be the fastest‑growing region. China’s pharmaceutical export volume surged 12 % YoY in 2023, and the country’s push for “Made in China 2025” includes expanding high‑purity chemical capacity. India’s generic‑drug sector, responsible for ~20 % of global API output, is scaling up its solvent stacks, while Japan and South Korea continue high‑value drug‑discovery activities that demand ultra‑pure reagents. Investment in new production facilities and joint ventures with Western firms accelerates market expansion.
Key Highlights:
How is regulatory evolution influencing regional demand for 1‑Bromopane for Pharmaceutical Use?
Regulatory bodies worldwide are tightening impurity limits for solvents used in drug synthesis. The United States Pharmacopeia (USP <1125>) and European Pharmacopoeia have lowered acceptable impurity thresholds, making high‑purity 1‑Bromopane essential. Meanwhile, the China Pharmacopoeia’s recent amendment requires ≥99.5 % purity for API‑scale batches, prompting manufacturers to qualify new supply sources. These stricter standards uniformly raise demand across regions, but the speed of compliance varies, creating short‑term supply gaps especially in emerging markets.
Key Highlights:
United States, China, India, Germany and Singapore are emerging as primary investment hubs. In the United States, major pharmaceutical clusters are establishing dedicated solvent‑purification lines. China’s strategic plan to become a global API supplier has attracted joint ventures between domestic firms and Albemarle. India’s “Pharma Vision 2025” incentivizes local production of high‑purity reagents. Germany’s strong specialty‑chemical base provides a gateway to the EU market, while Singapore’s logistics hub enables efficient distribution across Southeast Asia.
Global pharma firms are committing to greener manufacturing footprints, and 1‑Bromopane is positioned as a lower‑toxicity alternative to chlorinated solvents such as dichloromethane. Europe’s EU Green Deal and United States’ EPA voluntary programs encourage substitution with solvents that have lower ozone‑depletion potential. Consequently, European manufacturers are accelerating the transition to 1‑Bromopane, while Asian producers are upgrading distillation capacities to meet the required purity while reducing waste streams.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Albemarle, Chemtura, ICL, Weifang Longwei, Solaris Chemtech, Longsheng Chemical, Tongcheng Medical, Shandong Moris Tech, Shenrunfa, Shouguang Fukang Pharmaceutical, among others.
-> Key growth drivers include rising demand for high‑purity intermediates in oncology and antiviral drug pipelines, stricter regulatory requirements for solvent purity, and increased investment in API manufacturing capacity in North America and Asia‑Pacific.
-> Asia-Pacific is the fastest‑growing region, driven by China’s expanding API sector, while North America remains the largest revenue contributor due to stringent pharmaceutical standards.
-> Emerging trends include green‑chemistry initiatives that promote solvent recovery, digitalization of supply‑chain traceability, and the development of bio‑based brominated solvents as sustainable alternatives.
